Home Featured Page 92

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Introducing the Psychedelic News Feed

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro...

PT448 – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy

Reunion Neuroscience Inc. to Participate in October Investor Conferences

Clearmind Medicine to Present at the 8th Annual Dawson James Conference...

The Premiere of our New Short Film Vital Psychedelic Training: Creating...

Gratitude Revealed: Film Screening and Q&A with Director Louie Schwartzberg

Sunstone Therapies Announces Expansion of Innovative Dyad Study

PT447 – Exile & Ecstasy: The Intersection of Jewish Culture, Spirituality,...

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and...

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Introducing the Psychedelic News Feed

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro...

PT448 – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy

Reunion Neuroscience Inc. to Participate in October Investor Conferences

Clearmind Medicine to Present at the 8th Annual Dawson James Conference...

The Premiere of our New Short Film Vital Psychedelic Training: Creating...

Gratitude Revealed: Film Screening and Q&A with Director Louie Schwartzberg

Sunstone Therapies Announces Expansion of Innovative Dyad Study

PT447 – Exile & Ecstasy: The Intersection of Jewish Culture, Spirituality,...

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and...

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY